Recherche Images Maps Play YouTube Actualités Gmail Drive Plus »
Connexion
Les utilisateurs de lecteurs d'écran peuvent cliquer sur ce lien pour activer le mode d'accessibilité. Celui-ci propose les mêmes fonctionnalités principales, mais il est optimisé pour votre lecteur d'écran.

Brevets

  1. Recherche avancée dans les brevets
Numéro de publicationUS20050176153 A1
Type de publicationDemande
Numéro de demandeUS 10/979,054
Date de publication11 août 2005
Date de dépôt1 nov. 2004
Date de priorité2 févr. 2000
Autre référence de publicationCA2398203A1, CN1193228C, CN1394280A, DE60116056D1, DE60116056T2, EP1252514A2, EP1252514B1, EP1645876A2, EP1645876A3, US6475372, US6890421, US20020125145, WO2001057510A2, WO2001057510A3
Numéro de publication10979054, 979054, US 2005/0176153 A1, US 2005/176153 A1, US 20050176153 A1, US 20050176153A1, US 2005176153 A1, US 2005176153A1, US-A1-20050176153, US-A1-2005176153, US2005/0176153A1, US2005/176153A1, US20050176153 A1, US20050176153A1, US2005176153 A1, US2005176153A1
InventeursTimothy O'Hara, Mahyar Kermani
Cessionnaire d'origineLifescan, Inc
Exporter la citationBiBTeX, EndNote, RefMan
Liens externes: USPTO, Cession USPTO, Espacenet
Electrochemical methods and devices for use in the determination of hematocrit corrected analyte concentrations
US 20050176153 A1
Résumé
Methods and devices for determining the concentration of an analyte in a physiological sample are provided. In the subject methods, the physiological sample is introduced into an electrochemical cell having a working and reference electrode. A first electric potential is applied to the cell and the resultant cell current over a period of time is measured to determine a first time-current transient. A second electric potential of opposite polarity is then applied and a second a time-current transient is determined. The preliminary concentration of the analyte is then calculated from the first and/or second time-current transient. This preliminary analyte concentration less a background value is then multiplied by a hematocrit correction factor to obtain the analyte concentration in the sample, where the hematocrit correction factor is a function of the preliminary analyte concentration and the variable γ of the electrochemical cell. The subject methods and devices are suited for use in the determination of a wide variety of analytes in a wide variety of samples, and are particularly suited for the determination of analytes in whole blood or derivatives thereof, where an analyte of particular interest is glucose.
Images(2)
Previous page
Next page
Revendications(15)
1-20. (canceled)
21. An electrochemical cell for determining the concentration of an analyte in a physiological sample, the electrochemical cell comprising:
a working electrode;
a reference electrode;
a spacer layer between the working and reference electrodes; and
a reaction zone defined by the spacer layer and the working and reference electrodes, said reaction zone comprising an enzyme for producing an electrochemical signal in the presence of the analyte, wherein the reaction zone has a volume of from about 0.1 μl to about 10 μl;
wherein the electrochemical cell provides a measurement that correlates with the concentration of the analyte in the physiological sample within a period from about 3 to about 20 seconds.
22. The electrochemical cell of claim 21, wherein the reaction zone of from about 0.9 μl to about 1.6 μl;
23. The electrochemical cell of claim 21, wherein the period is from about 4 to about 10 seconds.
24. The electrochemical cell of claim 21, wherein the analyte is glucose and the enzyme is glucose oxidase.
25. The electrochemical cell of claim 1, wherein said reaction zone further comprises a mediator.
26. The electrochemical cell of claim 25, wherein said mediator is ferricyanide.
27. A system for determining the concentration of an analyte in a physiological sample, the system comprising:
a test strip comprising the electrochemical cell of claim 21; and
a meter for receiving the test strip, the meter comprising means for applying a first constant electric potential between the working and the reference electrodes over a first period of time to obtain a first time-current transient and for applying a second constant electric potential between the working and the reference electrodes over a second period of time to obtain a second time-current transient, and comprising means for deriving an analyte concentration from said first and second time-current transients.
28. A method for determining the concentration of an analyte in a physiological sample, the method comprising:
providing the electrochemical cell of claim 1;
introducing the sample into the reaction zone of the electrochemical cell;
applying a constant electric potential between the working and the reference electrodes;
observing a change in current between the electrodes over first period of time from about 3 to about 20 seconds to obtain a first time-current transient;
applying a second constant electric potential between the working and the reference electrodes;
observing a change in current between the electrodes over a second period of time from about 1 to about 10 seconds to obtain a second time-current transient; and
deriving an analyte concentration from said first and second time-current transients.
29. The method of claim 28 wherein the total amount of time required to obtain the first and second time-current transients is less than about 30 seconds.
30. The method of claim 29 wherein the total amount of time required to obtain the first and second time-current transients is less than about 20 seconds.
31. The method of claim 30 wherein the total amount of time required to obtain the first and second time-current transients is less than about 14 seconds.
32. The method of claim 28 wherein the magnitude of the first applied electric potential is opposite that of the magnitude of the second applied electric potential.
33. The method of claim 28 wherein the magnitude of the first applied electric potential is from about 0 to about −0.6 V and the second constant electric potential typically ranges from about 0 to about +0.6 V.
34. The method of claim 33 wherein the magnitude of the first applied electric potential is from about −0.2 to −0.4 V and the second constant electric potential typically ranges from about +0.2 to +0.4 V.
Description
    FIELD OF THE INVENTION
  • [0001]
    The field of this invention is analyte determination, particularly electrochemical analyte determination and more particularly the electrochemical determination of blood analytes.
  • BACKGROUND
  • [0002]
    Analyte detection in physiological fluids, e.g. blood or blood derived products, is of ever increasing importance to today's society. Analyte detection assays find use in a variety of applications, including clinical laboratory testing, home testing, etc., where the results of such testing play a prominent role in diagnosis and management in a variety of disease conditions. Analytes of interest include glucose for diabetes management, cholesterol, and the like. In response to this growing importance of analyte detection, a variety of analyte detection protocols and devices for both clinical and home use have been developed.
  • [0003]
    One type of method that is employed for analyte detection is an electrochemical method. In such methods, an aqueous liquid sample is placed into a reaction zone in an electrochemical cell comprising two electrodes, i.e. a reference and working electrode, where the electrodes have an impedance which renders them suitable for amperometric measurement. The component to be analyzed is allowed to react directly with an electrode, or directly or indirectly with a redox reagent to form an oxidisable (or reducible) substance in an amount corresponding to the concentration of the component to be analyzed. i.e. analyte. The quantity of the oxidisable (or reducible) substance present is then estimated electrochemically and related to the amount of analyte present in the initial sample.
  • [0004]
    Where the physiological sample being assayed is whole blood or a derivative thereof, the hematocrit of the sample can be a source of analytical error in the ultimate analyte concentration measurement. For example, in electrochemical measurement protocols where the analyte concentration is derived from observed time-current transients, hematocrit can slow the equilibration chemistry in the electrochemical cell and/or slow the enzyme kinetics by increasing the sample viscosity in the cell, thereby attenuating the time current response and causing analytical error.
  • [0005]
    As such, there is great interest in the development of methods of at least minimizing the hematocrit originated analytical error. In certain protocols, blood filtering membranes are employed to remove red blood cells and thereby minimize the hematocrit effect. These particular protocols are unsatisfactory in that increased sample volumes and testing times are required. Other protocols focus on the determination of the capillary fill time. However, these protocols add complexity to both the strips and devices that are used to read them. In yet other embodiments, hematocrit is separately determined using two additional electrodes, which also results in more complex and expensive strips/devices.
  • [0006]
    As such, there is continued interest in the identification of new methods for electrochemically measuring the concentration of an analyte in a physiological sample, where the method minimizes the analytical error which originates with the hematocrit of the sample.
  • [0000]
    Relevant Literature
  • [0007]
    Patent documents of interest include: U.S. Pat. No. 5,942,102 and WO 97/18465.
  • SUMMARY OF THE INVENTION
  • [0008]
    Methods and devices for determining the concentration of an analyte in a physiological sample are provided. In the subject methods, the physiological sample is introduced into an electrochemical cell having a working and reference electrode. A first electric potential is applied to the cell and the resultant cell current over a first period of time is measured to determine a first time-current transient. A second electric potential of opposite polarity is then applied to the cell and a second time-current transient is determined. The preliminary concentration of the analyte (C0) is then calculated from the first and/or second time-current transients. This preliminary analyte concentration, less a background value, is then multiplied by a hematocrit correction factor to obtain the analyte concentration in the sample, where the hematocrit correction factor is a function of the preliminary analyte concentration and the ratio of 2 current values (γ) within the time-current transient of the electrochemical cell. The subject methods and devices are suited for use in the determination of a wide variety of analytes in a wide variety of samples, and are particularly suited for the determination of analytes in whole blood or derivatives thereof, where an analyte of particular interest is glucose.
  • BRIEF DESCRIPTION OF THE FIGURES
  • [0009]
    FIG. 1 provides a three-dimensional graph of C0, γ and α(C0, γ) derived from experimental data using a wide range of glucose and hematocrit values.
  • DESCRIPTION OF THE SPECIFIC EMBODIMENTS
  • [0010]
    Methods and devices for determining the concentration of an analyte in a physiological sample are provided. In the subject methods, the physiological sample is introduced into an electrochemical cell having a working and reference electrode. A first electric potential is applied to the cell and the resultant cell current over a first period of time is measured to determine a first time-current transient. A second electric potential of opposite polarity is then applied to the cell and a second a time-current transient is determined. The preliminary concentration of the analyte is then calculated from the first and/or second time-current transient. This preliminary analyte concentration, less a background value, is then multiplied by a hematocrit correction factor to obtain the analyte concentration in the sample, where the hematocrit correction factor is a function of the preliminary analyte concentration and the variable γ of the electrochemical cell. The subject methods and devices are suited for use in the determination of a wide variety of analytes in a wide variety of samples, and are particularly suited for use in the determination of analytes in whole blood or derivatives thereof, where an analyte of particular interest is glucose. In further describing the subject invention, the subject methods will be described first followed by a review of a representative device for use in practicing the subject methods.
  • [0011]
    Before the subject invention is described further, it is to be understood that the invention is not limited to the particular embodiments of the invention described below, as variations of the particular embodiments may be made and still fall within the scope of the appended claims. It is also to be understood that the terminology employed is for the purpose of describing particular embodiments, and is not intended to be limiting. Instead, the scope of the present invention will be established by the appended claims.
  • [0012]
    In this specification and the appended claims, singular references include the plural, unless the context clearly dictates otherwise. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood to one of ordinary skill in the art to which this invention belongs.
  • [0000]
    Methods
  • [0013]
    As summarized above, the subject invention provides a method for determining a hematocrit corrected analyte concentration value in a physiological sample. By hematocrit corrected analyte concentration is meant that the analyte concentration value determined using the subject methods has been modulated or changed to remove substantially all contribution of hematocrit to the value. In other words, the concentration value that is determined using the subject methods has been modified so that any contribution to the value from the hematocrit of the sample that would be present in the value but for the practicing of the subject methods is removed. As such, the hematocrit signal is deconvoluted from the analyte signal in the subject methods, and only the analyte signal is employed in arriving at the final hematocrit corrected analyte concentration.
  • [0014]
    The first step in the subject methods is to introduce a quantity of the physiological sample of interest into an electrochemical cell that includes spaced apart working and reference electrodes and a redox reagent system. The physiological sample may vary, but in many embodiments is generally whole blood or a derivative or fraction thereof, where whole blood is of particular interest in many embodiments. The amount of physiological sample, e.g. blood, that is introduced into the reaction area of the test strip varies, but generally ranges from about 0.1 to 10 μL, usually from about 0.9 to 1.6 μL. The sample is introduced into the reaction area using any convenient protocol, where the sample may be injected into the reaction area, allowed to wick into the reaction area, and the like, as may be convenient.
  • [0015]
    While the subject methods may be used, in principle, with any type of electrochemical cell having spaced apart working and reference electrodes and a redox reagent system, in many embodiments the subject methods employ an electrochemical test strip. The electrochemical test strips employed in these embodiments of the subject invention are made up of two opposing metal electrodes separated by a thin spacer layer, where these components define a reaction area or zone in which is located a redox reagent system.
  • [0016]
    In certain embodiments of these electrochemical test strips, the working and reference electrodes are generally configured in the form of elongated rectangular strips. Typically, the length of the electrodes ranges from about 1.9 to 4.5 cm, usually from about 2.0 to 2.8 cm. The width of the electrodes ranges from about 0.38 to 0.76 cm, usually from about 0.51 to 0.67 cm. The reference electrodes typically have a thickness ranging from about 10 to 100 nm and usually from about 10 to 20 nm. In certain embodiments, the length of one of the electrodes is shorter than the length of the other electrode, typically about 0.32 cm. The shorter electrode may be the working or reference electrode.
  • [0017]
    The working and reference electrodes are further characterized in that at least the surface of the electrodes that faces the reaction area in the strip is a metal, where metals of interest include palladium, gold, platinum, silver, iridium, carbon, doped tin oxide, stainless steel and the like. In many embodiments, the metal is gold or palladium. While in principle the entire electrode may be made of the metal, each of the electrodes is generally made up of an inert support material on the surface of which is present a thin layer of the metal component of the electrode. In these more common embodiments, the thickness of the inert backing material typically ranges from about 51 to 356 μm, usually from about 102 to 153 μm while the thickness of the metal layer typically ranges from about 10 to 100 nm and usually from about 10 to 40 nm, e.g. a sputtered metal layer. Any convenient inert backing material may be employed in the subject electrodes, where typically the material is a rigid material that is capable of providing structural support to the electrode and, in turn, the electrochemical test strip as a whole. Suitable materials that may be employed as the backing substrate include plastics, e.g. PET, PETG, polyimide, polycarbonate, polystyrene, silicon, ceramic, glass, and the like.
  • [0018]
    A feature of the electrochemical test strips used in these embodiments of the subject methods is that the working and reference electrodes as described above face each other and are separated by only a short distance, such that the distance between the working and reference electrode in the reaction zone or area of the electrochemical test strip is extremely small. This minimal spacing of the working and reference electrodes in the subject test strips is a result of the presence of a thin spacer layer positioned or sandwiched between the working and reference electrodes. The thickness of this spacer layer generally should be less than or equal to 500 μm, and usually ranges from about 102 to 153 μm. The spacer layer is cut so as to provide a reaction zone or area with at least an inlet port into the reaction zone, and generally an outlet port out of the reaction zone as well. The spacer layer may have a circular reaction area cut with side inlet and outlet vents or ports, or other configurations, e.g. square, triangular, rectangular, irregular shaped reaction areas, etc. The spacer layer may be fabricated from any convenient material, where representative suitable materials include PET, PETG, polyimide. polycarbonate, and the like, where the surfaces of the spacer layer may be treated so as to be adhesive with respect to their respective electrodes and thereby maintain the structure of the electrochemical test strip. Of particular interest is the use of a die-cut double-sided adhesive strip as the spacer layer.
  • [0019]
    The electrochemical test strips used in these embodiments of the subject invention include a reaction zone or area that is defined by the working electrode, the reference electrode and the spacer layer, where these elements are described above. Specifically, the working and reference electrodes define the top and bottom of the reaction area, while the spacer layer defines the walls of the reaction area. The volume of the reaction area is at least about 0.1 μL, usually at least about 1 μL and more usually at least about 1.5 μL, where the volume may be as large as 10 μL or larger. As mentioned above, the reaction area generally includes at least an inlet port, and in many embodiments also includes an outlet port. The cross-sectional area of the inlet and outlet ports may vary as long as it is sufficiently large to provide an effective entrance or exit of fluid from the reaction area, but generally ranges from about 9×10−4 to 5×10−3 cm2, usually from about 1.3×10−3 to 2.5×10−3cm2.
  • [0020]
    Present in the reaction area is a redox reagent system, which reagent system provides for the species that is measured by the electrode and therefore is used to derive the concentration of analyte in a physiological sample. The redox reagent system present in the reaction area typically includes at least an enzyme(s) and a mediator. In many embodiments, the enzyme member(s) of the redox reagent system is an enzyme or plurality of enzymes that work in concert to oxidize the analyte of interest. In other words, the enzyme component of the redox reagent system is made up of a single analyte oxidizing enzyme or a collection of two or more enzymes that work in concert to oxidize the analyte of interest. Enzymes of interest include oxidases, dehydrogenases, lipases, kinases, diphorases, quinoproteins, and the like.
  • [0021]
    The specific enzyme present in the reaction area depends on the particular analyte for which the electrochemical test strip is designed to detect, where representative enzymes include: glucose oxidase, glucose dehydrogenase, cholesterol esterase, cholesterol oxidase, lipoprotein lipase, glycerol kinase, glycerol-3-phosphate oxidase, lactate oxidase, lactate dehydrogenase, pyruvate oxidase, alcohol oxidase, bilirubin oxidase, uricase, and the like. In many preferred embodiments where the analyte of interest is glucose, the enzyme component of the redox reagent system is a glucose oxidizing enzyme. e.g. a glucose oxidase or glucose dehydrogenase.
  • [0022]
    The second component of the redox reagent system is a mediator component, which is made up of one or more mediator agents. A variety of different mediator agents are known in the art and include: ferricyanide, phenazine ethosulphate, phenazine methosulfate, pheylenediamine, 1-methoxy-phenazine methosulfate, 2,6-dimethyl-1,4-benzoquinone, 2,5-dichloro-1,4-benzoquinone, ferrocene derivatives, osmium bipyridyl complexes, ruthenium complexes, and the like. In those embodiments where glucose in the analyte of interest and glucose oxidase or glucose dehydrogenase are the enzyme components, mediators of particular interest are ferricyanide, and the like.
  • [0023]
    Other reagents that may be present in the reaction area include buffering agents, e.g. citraconate, citrate, malic, maleic, phosphate, “Good” buffers and the like. Yet other agents that may be present include: divalent cations such as calcium chloride, and magnesium chloride; pyrroloquinoline quinone; types of surfactants such as Triton, Macol, Tetronic, Silwet, Zonyl, and Pluronic; stabilizing agents such as albumin, sucrose, trehalose, mannitol, and lactose.
  • [0024]
    The redox reagent system is generally present in dry form. The amounts of the various components may vary, where the amount of enzyme component typically ranges from about 1 to 100 mg/mL, usually from about 5 to 80 mg/mL; and the amount of mediator component typically ranges from about 5 to 1000 mM, usually from about 90 to 900 mM.
  • [0025]
    Following sample introduction, first and second time-current transients are obtained. The first and second time-current transients are obtained by applying a constant electric potential to the cell and observing the change in current over a period of time in the cell. In other words, first and second pulses are applied to the cell and the resultant time-current transients are observed. As such, the first time-current transient is obtained by applying a constant electric potential or first pulse to the cell, e.g. between the working and the reference electrodes, and observing the change in current over time between the electrodes, i.e. change in cell current, to obtain the first time-current transient. The magnitude of the first applied electric potential generally ranges from about 0 to −0.6 V, usually from about −0.2 to −0.4 V. The length of time over which the current between the electrodes is observed to obtain the first time-current transient typically ranges from about 3 to 20 seconds, usually from about 4 to 10 seconds.
  • [0026]
    The second time current is obtained by applying a second constant electric potential or second pulse, typically of opposite polarity from the first constant electric potential, to the electrodes and observing the change in current between the electrodes for a second period of time. The magnitude of this second constant electric potential typically ranges from about 0 to +0.6 V, usually from about +0.2 to +0.4 V, where in many embodiments the magnitude of the second electric potential is the same as the magnitude of the first electric potential. The second time period typically ranges from about 1 to 10 seconds, usually from about 2 to 4 seconds. By observing the change in current between the electrodes over this second period of time, a second time-current transient for the cell is determined.
  • [0027]
    The overall time period required to obtain the requisite first and second time-current transients, as described above, is relatively short in certain embodiments. In such embodiments, the total amount of time required to obtain the first and second time-current transients is less than about 30 seconds, usually less than about 20 seconds and more usually less than about 14 seconds.
  • [0028]
    The next step in the subject methods is to use the observed first and second time-current transients, obtained as described above, to determine: (a) the variable γ of the electrochemical cell used in the subject methods; and (b) a preliminary analyte concentration for the analyte of interest in the sample.
  • [0029]
    The variable γ employed in the subject methods is defined to describe the deviation of the electrochemical cell from ideality. By way of background, it should be noted that γ should approach unity under ideal conditions, i.e. reagent equilibration and glucose reaction are complete before the end of the first pulse. Any of these conditions not being complete will cause the ratio to deviate fron non-unity values. The numerator of γ is defined as the steady-state current observed following application of the second electric potential to the cell, i.e. predicted value at t=∞ of the second time-current transient. The denominator is defined as the average current over a short time period near the end of the first period of time, i.e. near the end of the application of the first electric potential or first pulse. The short period of time from which the average current is determined typically ranges from 0.2 to 2 seconds, usually from about 0.2 to 1.5 seconds and more usually from about 0.2 to 1.25 seconds, where in many embodiments the short period of time is about 0.3 second. The average current is determined at a time near the end of the first time period, typically within about 0.1 to 1 second. In certain embodiments, the variable γ is described by the formula:
    γ=iss/ipp
    where:
  • [0030]
    iss is the steady-state current of the second applied electric potential; and
  • [0031]
    ipp is the average current over a short period of time near the end of first time period, i.e. near the end of the time during which the first electric potential is applied to the cell. For example, where the first time period is 10 seconds long, the average current may be the average current from 8.5 to 9.5 seconds of the 10 second long period, which is a 1.0 second time period 0.5 seconds from the end of the first time period As mentioned above, the first and second time-current transients are also employed to derive a preliminary analyte concentration value for the sample being assayed. In many embodiments, the preliminary analyte concentration is determined by using the following equations:
    i(t)=i ss{1+4 exp(−4π2 Dt/L 2)}
    iss=2 FADCo/L
    where
  • [0032]
    iss is the steady-state current following application of the second electric potential;
  • [0033]
    i is the measured current which is a function of time
  • [0034]
    D is the diffusion coefficient of the cell, where this coefficient may be determined from Fick's first law, i.e. J(x,t)=−DdC(x,t)/dx
  • [0035]
    L is the spacer thickness;
  • [0036]
    t is the time for the application of the 2nd electric potential where t=0 for the beginning of the pulse
  • [0037]
    C0 is the preliminary concentration of the analyte;
  • [0038]
    F is faraday's constant, i.e. 9.648533 104C/mol; and
  • [0039]
    A is the area of the working electrode.
  • [0040]
    Using the above equations and steps, the observed first and second time-current transients are used to determine the variable γ of the electrochemical cell employed in the subject method and the preliminary concentration value of the analyte of interest in the assayed physiological sample.
  • [0041]
    From the determined variable γ and preliminary analyte concentration value, a hematocrit correction factor is determined, which hematocrit correction factor is used to obtain a hematocrit corrected analyte concentration value from the initial or preliminary analyte concentration value described above. The hematocrit correction factor is a factor with which the preliminary analyte concentration (typically less a background value) may be multiplied in order to obtain a hematocrit corrected analyte concentration value, i.e. a concentration value from which the hematocrit component has been removed. The hematocrit correction factor is a function of both the preliminary analyte concentration value and the variable γ of the electrochemical cell.
  • [0042]
    Any hematocrit correction factor that can be multiplied by the preliminary concentration value (usually less a background value, as described in greater detail below) may be employed in the subject methods. One class of hematocrit correction factors that find use in the subject methods are those that are derived from a three dimensional graph of C0, γ and α(C0, γ) obtained from experimental data using a wide range of analyte and hematocrit values. The hematocrit correction factor (α(C0, γ)) is determined using the formula:
    α(C 0, γ)=actual concentration/(C 0−Background Value)
    (For example, where the analyte is glucose, α(C0, γ) in many embodiments equals the glucose concentration as determined using the Yellow Springs Instrument glucose analyzer model 23A (as described in U.S. Pat. No. 5,968,760 the disclosure of which is herein incorporated by reference) divided by the C0 less a background value, e.g. 22 mg/dL). This class of hematocrit correction factors are typically equations which fit a smooth surface function that minimizes the error between the predicted and actual data. See e.g. the experimental section, infra. One representative hematocrit correction factor that finds use in the subject methods is:
    1/((0.6637)+((4.9466*ln(C 0))/C 0)+(−0.4012*ln(γ)))
  • [0043]
    In determining the hematocrit corrected concentration of analyte according to the subject invention, the preliminary analyte concentration (C0) as determined above, less a background signal value, is multiplied by the hematocrit correction factor. The background value that is subtracted from the preliminary concentration value depends on the analyte being measured. For glucose, this value typically ranges from about 0 to 40 mg/dL, usually from about 8 to 25 mg/dL, where in many embodiments the background value is about 22 mg/dL or is 22 mg/dL.
  • [0044]
    Generally, the following formula is employed to determine the hematocrit corrected analyte concentration according to the subject invention:
    hematocrit corrected concentration hematocrit correction factor×[C 0−β]
    where
  • [0045]
    β is the background value; and
  • [0046]
    C0 is the preliminary analyte concentration.
  • [0047]
    The above described methods yield a hematocrit corrected analyte concentration value, i.e. a concentration value in which the hematocrit component has been deconvoluted and removed. As such, the above described methods provide for an accurate value of the concentration of the analyte in the sample being assayed.
  • [0048]
    The above computational steps of the subject method may be accomplished manually or through the use of an automated computing means, where in many embodiments the use of an automated computing means, such as is described in connection with the subject devices discussed below, is of interest.
  • [0000]
    Devices
  • [0049]
    Also provided by the subject invention are meters for use in practicing the subject invention. The subject meters are typically meters for amperometrically measuring the hematocrit corrected concentration of an analyte in a physiological sample. The subject meters typically include: (a) a means for applying a first electric potential to an electrochemical cell into which the sample has been introduced and measuring cell current as a function of time to obtain a first time-current transient; (b) a means for applying a second electric potential to the electrochemical cell and measuring cell current as a function of time to obtain a second time-current transient; (c) a means for determining a preliminary analyte concentration value and a variable γ from said first and second time-currents; and (d) a means for removing the hematocrit component from the preliminary concentration value to derive the hematocrit corrected analyte concentration in said sample. Means (a) and (b) may be any suitable means, where representative means are described in WO 97/18465 and U.S. Pat. No. 5,942,102; the disclosures of which are herein incorporated by reference. Means (c) and (d) are typically computing means present in the meter which are capable of using the measured first and second time current transients to ultimately obtain the hematocrit corrected analyte concentration. As such, means (c) is typically a means that is capable of determining the preliminary concentration of the analyte of interest and the variable γ from the first and second time-current transients using the equations described above. Likewise, means (d) is typically a means that is capable of determining the hematocrit corrected analyte concentration using the equations described above, where this means typically comprises the hematocrit correction factor.
  • [0050]
    The following examples are offered by way of illustration and not by way of limitation.
  • EXPERIMENTAL
  • [0000]
    I. Electrochemical Test Strip Preparation
  • [0051]
    An electrochemical test strip consisting of two metallized electrodes oriented in a sandwich configuration was prepared as follows. The top layer of the test strip was a gold sputtered Mylar strip. The middle layer was a double-sided adhesive with a punched hole that defined the reaction zone or area. The punched hole was a circle with two juxtaposed rectangular inlet and outlet channels. The bottom layer of the test strip was sputtered palladium on Mylar. A film of ferricyanide and glucose dehydrogenase PQQ was deposited on the palladium sputtered surface.
  • [0000]
    II. Generation of Experimental Data
  • [0052]
    First and second time current transients for a number of different samples varying by glucose concentration and hematocrit were obtained as follows. Sample was applied to the strip which actuated an applied potential of −0.03V for a period of 10 seconds which was then followed by a second pulse of +0.3V for a period of 3 to 10 seconds (where these electrode potentials are with respect to the gold electrode).
  • [0000]
    III. Derivation of Hematocrit Correction Factor for Glucose
  • [0053]
    For a wide range of glucose and hematocrit values measured as described above, C0, the variable γ and α(C0, γ) were derived.
  • [0054]
    C0 was derived using the equations:
    i(t)=i ss{1+4 exp(−4π2 Dt/L 2)}
    iss=2 FADC0/L
    where
  • [0055]
    iss is the steady-state current following application of the second electric potential;
  • [0056]
    i is the measured current which is a function of time
  • [0057]
    D is the diffusion coefficient of the cell, where this coefficient may be determined from Fick's first law, i.e. J(x,t)=−DdC(x,t)/dx
  • [0058]
    L is the spacer thickness;
  • [0059]
    t is the time for the application of the 2nd electric potential where t=0 for the beginning of the pulse;
  • [0060]
    C0 is the preliminary concentration of the analyte;
  • [0061]
    F is faraday's constant, i.e. 9.6485×104C/mol; and
  • [0062]
    A is the area of the electrode surface.
  • [0000]
    The variable γ was derived using the equation:
    γ=i ss /i pp
    where:
  • [0063]
    iss is the steady-state current of the second applied electric potential or second pulse; and
  • [0064]
    ipp is the average current from 8.5 to 9.5 seconds of the 10 s long period during which the first pulse was applied.
  • [0065]
    α(C0, γ) was determined using the equation:
    α(C 0, γ)=YSI concentration/(C 0−22 mg/dL)
    where YSI is the glucose concentration as determined using the Yellow Springs Instrument glucose analyzer model 23A (as described in U.S. Pat. No. 5,968,760 the disclosure of which is herein incorporated by reference).
  • [0066]
    A three-dimensional graph of C0, γ and α(C0, γ) as determined above for a wide range of glucose and hematocrit values was prepared and is shown in FIG. 1. A simple equation fit was then performed on the graph to define the surface. The residual of the fitted data was monitored to ascertain the quality of the model equation. The empirical equation was found to be:
    Hematocrit Correction Factor=1/((0.6637)+((4.9466*ln(C 0))/C 0)+(−0.4012*ln(γ)))
    The above correction factor was found to be valid for those situations where the γ>0.7 and C0>40 mg/dL.
    IV. Comparison of Hematocrit Corrected Values to YSI determined Values.
  • [0067]
    A prediction data set was generated by testing several glucose strips with a wide range of glucose and hematocrit levels. From this data a hematocrit correction equation was derived using a model which fits the terms C0, γ, and α(C0, γ). It was found that using the hematocrit correction equation on the prediction data set causes the majority of data points to fall within +/−15%. It was also found that the bias of the glucose results to 42% hematocrit, indicating that the hematocrit effect on this data set is minimal. In order to confirm this algorithm, another batch of glucose sesnsors was tested with a different blood donor. It was found that the algorithm still corrects for the hematocrit effect in a manner analogous to the earlier findings.
  • [0068]
    The above results and discussion demonstrate that subject invention provides a simple and powerful tool to obtain analyte concentration values in which hematocrit derived error is substantially if not entirely eliminated. As the subject methods rely solely on the measurement of time-current transients, they may be practiced with relatively simple electrochemical devices. Furthermore, only small sample volumes need be employed and relatively quick assay times are provided. As such, the subject invention represents a significant contribution to the art.
  • [0069]
    All publications and patents cited in this specification are herein incorporated by reference as if each individual publication or patent were specifically and individually indicated to be incorporated by reference. The citation of any publication is for its disclosure prior to the filing date and should not be construed as an admission that the present invention is not entitled to antedate such publication by virtue of prior invention.
  • [0070]
    Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it is readily apparent to those of ordinary skill in the art in light of the teachings of this invention that certain changes and modifications may be made thereto without departing from the spirit or scope of the appended claims.
Citations de brevets
Brevet cité Date de dépôt Date de publication Déposant Titre
US5089320 *5 janv. 199018 févr. 1992James River Ii, Inc.Resealable packaging material
US5353351 *9 juin 19924 oct. 1994At&T Bell LaboratoriesSecure teleconferencing
US5437999 *22 févr. 19941 août 1995Boehringer Mannheim CorporationElectrochemical sensor
US5628890 *27 sept. 199513 mai 1997Medisense, Inc.Electrochemical sensor
US5942102 *7 mai 199724 août 1999Usf Filtration And Separations Group Inc.Electrochemical method
US6475372 *2 févr. 20005 nov. 2002Lifescan, Inc.Electrochemical methods and devices for use in the determination of hematocrit corrected analyte concentrations
US20020092612 *22 févr. 200218 juil. 2002Davies Oliver William HardwickeRapid response glucose sensor
Référencé par
Brevet citant Date de dépôt Date de publication Déposant Titre
US72761464 oct. 20022 oct. 2007Roche Diagnostics Operations, Inc.Electrodes, methods, apparatuses comprising micro-electrode arrays
US72761475 mars 20032 oct. 2007Roche Diagnostics Operations, Inc.Method for determining the concentration of an analyte in a liquid sample using small volume samples and fast test times
US774937130 sept. 20056 juil. 2010Lifescan, Inc.Method and apparatus for rapid electrochemical analysis
US787504725 janv. 200725 janv. 2011Pelikan Technologies, Inc.Method and apparatus for a multi-use body fluid sampling device with sterility barrier release
US78921833 juil. 200322 févr. 2011Pelikan Technologies, Inc.Method and apparatus for body fluid sampling and analyte sensing
US790136521 mars 20078 mars 2011Pelikan Technologies, Inc.Method and apparatus for penetrating tissue
US790977413 févr. 200722 mars 2011Pelikan Technologies, Inc.Method and apparatus for penetrating tissue
US790977526 juin 200722 mars 2011Pelikan Technologies, Inc.Method and apparatus for lancet launching device integrated onto a blood-sampling cartridge
US790977729 sept. 200622 mars 2011Pelikan Technologies, IncMethod and apparatus for penetrating tissue
US790977820 avr. 200722 mars 2011Pelikan Technologies, Inc.Method and apparatus for penetrating tissue
US79144658 févr. 200729 mars 2011Pelikan Technologies, Inc.Method and apparatus for penetrating tissue
US793878729 sept. 200610 mai 2011Pelikan Technologies, Inc.Method and apparatus for penetrating tissue
US795958221 mars 200714 juin 2011Pelikan Technologies, Inc.Method and apparatus for penetrating tissue
US7972861 *13 mai 20055 juil. 2011Bayer Healthcare LlcMethods for performing hematocrit adjustment in glucose assays and devices for same
US797647616 mars 200712 juil. 2011Pelikan Technologies, Inc.Device and method for variable speed lancet
US798105522 déc. 200519 juil. 2011Pelikan Technologies, Inc.Tissue penetration device
US798105618 juin 200719 juil. 2011Pelikan Technologies, Inc.Methods and apparatus for lancet actuation
US798864421 mars 20072 août 2011Pelikan Technologies, Inc.Method and apparatus for a multi-use body fluid sampling device with sterility barrier release
US79886453 mai 20072 août 2011Pelikan Technologies, Inc.Self optimizing lancing device with adaptation means to temporal variations in cutaneous properties
US800744619 oct. 200630 août 2011Pelikan Technologies, Inc.Method and apparatus for penetrating tissue
US801677422 déc. 200513 sept. 2011Pelikan Technologies, Inc.Tissue penetration device
US802610421 oct. 200727 sept. 2011Bayer Healthcare LlcTransient decay amperometry
US806223111 oct. 200622 nov. 2011Pelikan Technologies, Inc.Method and apparatus for penetrating tissue
US807996010 oct. 200620 déc. 2011Pelikan Technologies, Inc.Methods and apparatus for lancet actuation
US812370026 juin 200728 févr. 2012Pelikan Technologies, Inc.Method and apparatus for lancet launching device integrated onto a blood-sampling cartridge
US814767414 nov. 20083 avr. 2012Bayer Healthcare LlcRapid-read gated amperometry
US815774810 janv. 200817 avr. 2012Pelikan Technologies, Inc.Methods and apparatus for lancet actuation
US816285322 déc. 200524 avr. 2012Pelikan Technologies, Inc.Tissue penetration device
US816316231 mars 200624 avr. 2012Lifescan, Inc.Methods and apparatus for analyzing a sample in the presence of interferents
US819742116 juil. 200712 juin 2012Pelikan Technologies, Inc.Method and apparatus for penetrating tissue
US819742314 déc. 201012 juin 2012Pelikan Technologies, Inc.Method and apparatus for penetrating tissue
US820223123 avr. 200719 juin 2012Sanofi-Aventis Deutschland GmbhMethod and apparatus for penetrating tissue
US820631722 déc. 200526 juin 2012Sanofi-Aventis Deutschland GmbhTissue penetration device
US820631926 août 201026 juin 2012Sanofi-Aventis Deutschland GmbhTissue penetration device
US821103722 déc. 20053 juil. 2012Pelikan Technologies, Inc.Tissue penetration device
US821615423 déc. 200510 juil. 2012Sanofi-Aventis Deutschland GmbhTissue penetration device
US822133422 déc. 201017 juil. 2012Sanofi-Aventis Deutschland GmbhMethod and apparatus for penetrating tissue
US823591518 déc. 20087 août 2012Sanofi-Aventis Deutschland GmbhMethod and apparatus for penetrating tissue
US825192110 juin 201028 août 2012Sanofi-Aventis Deutschland GmbhMethod and apparatus for body fluid sampling and analyte sensing
US82626141 juin 200411 sept. 2012Pelikan Technologies, Inc.Method and apparatus for fluid injection
US826787030 mai 200318 sept. 2012Sanofi-Aventis Deutschland GmbhMethod and apparatus for body fluid sampling with hybrid actuation
US828257629 sept. 20049 oct. 2012Sanofi-Aventis Deutschland GmbhMethod and apparatus for an improved sample capture device
US828257715 juin 20079 oct. 2012Sanofi-Aventis Deutschland GmbhMethod and apparatus for lancet launching device integrated onto a blood-sampling cartridge
US829691823 août 201030 oct. 2012Sanofi-Aventis Deutschland GmbhMethod of manufacturing a fluid sampling device with improved analyte detecting member configuration
US83337105 oct. 200518 déc. 2012Sanofi-Aventis Deutschland GmbhTissue penetration device
US83374194 oct. 200525 déc. 2012Sanofi-Aventis Deutschland GmbhTissue penetration device
US833742024 mars 200625 déc. 2012Sanofi-Aventis Deutschland GmbhTissue penetration device
US833742116 déc. 200825 déc. 2012Sanofi-Aventis Deutschland GmbhTissue penetration device
US834307523 déc. 20051 janv. 2013Sanofi-Aventis Deutschland GmbhTissue penetration device
US836099123 déc. 200529 janv. 2013Sanofi-Aventis Deutschland GmbhTissue penetration device
US836099225 nov. 200829 janv. 2013Sanofi-Aventis Deutschland GmbhMethod and apparatus for penetrating tissue
US83666373 déc. 20085 févr. 2013Sanofi-Aventis Deutschland GmbhMethod and apparatus for penetrating tissue
US837201630 sept. 200812 févr. 2013Sanofi-Aventis Deutschland GmbhMethod and apparatus for body fluid sampling and analyte sensing
US83826826 févr. 200726 févr. 2013Sanofi-Aventis Deutschland GmbhMethod and apparatus for penetrating tissue
US83826837 mars 201226 févr. 2013Sanofi-Aventis Deutschland GmbhTissue penetration device
US838855127 mai 20085 mars 2013Sanofi-Aventis Deutschland GmbhMethod and apparatus for multi-use body fluid sampling device with sterility barrier release
US84038641 mai 200626 mars 2013Sanofi-Aventis Deutschland GmbhMethod and apparatus for penetrating tissue
US840410011 sept. 200626 mars 2013Bayer Healthcare LlcGated voltammetry
US84041022 juil. 201026 mars 2013Lifescan, Inc.Method and apparatus for rapid electrochemical analysis
US841450316 mars 20079 avr. 2013Sanofi-Aventis Deutschland GmbhMethods and apparatus for lancet actuation
US842575719 déc. 200723 avr. 2013Bayer Healthcare LlcGated amperometry
US843082826 janv. 200730 avr. 2013Sanofi-Aventis Deutschland GmbhMethod and apparatus for a multi-use body fluid sampling device with sterility barrier release
US843519019 janv. 20077 mai 2013Sanofi-Aventis Deutschland GmbhMethod and apparatus for penetrating tissue
US843987226 avr. 201014 mai 2013Sanofi-Aventis Deutschland GmbhApparatus and method for penetration with shaft having a sensor for sensing penetration depth
US847060416 août 201125 juin 2013Bayer Healthcare LlcTransient decay amperometry
US849150016 avr. 200723 juil. 2013Sanofi-Aventis Deutschland GmbhMethods and apparatus for lancet actuation
US849660116 avr. 200730 juil. 2013Sanofi-Aventis Deutschland GmbhMethods and apparatus for lancet actuation
US85456933 sept. 20101 oct. 2013Lifescan Scotland LimitedAnalyte measurment method and system
US855682927 janv. 200915 oct. 2013Sanofi-Aventis Deutschland GmbhMethod and apparatus for penetrating tissue
US856254516 déc. 200822 oct. 2013Sanofi-Aventis Deutschland GmbhTissue penetration device
US857416826 mars 20075 nov. 2013Sanofi-Aventis Deutschland GmbhMethod and apparatus for a multi-use body fluid sampling device with analyte sensing
US857489530 déc. 20035 nov. 2013Sanofi-Aventis Deutschland GmbhMethod and apparatus using optical techniques to measure analyte levels
US85798316 oct. 200612 nov. 2013Sanofi-Aventis Deutschland GmbhMethod and apparatus for penetrating tissue
US862293018 juil. 20117 janv. 2014Sanofi-Aventis Deutschland GmbhTissue penetration device
US86366731 déc. 200828 janv. 2014Sanofi-Aventis Deutschland GmbhTissue penetration device
US864164327 avr. 20064 févr. 2014Sanofi-Aventis Deutschland GmbhSampling module device and method
US864164423 avr. 20084 févr. 2014Sanofi-Aventis Deutschland GmbhBlood testing apparatus having a rotatable cartridge with multiple lancing elements and testing means
US864748928 févr. 201311 févr. 2014Bayer Healthcare LlcGated voltammetry devices
US865283126 mars 200818 févr. 2014Sanofi-Aventis Deutschland GmbhMethod and apparatus for analyte measurement test time
US866865631 déc. 200411 mars 2014Sanofi-Aventis Deutschland GmbhMethod and apparatus for improving fluidic flow and sample capture
US867903316 juin 201125 mars 2014Sanofi-Aventis Deutschland GmbhTissue penetration device
US868838630 juin 20101 avr. 2014Lifescan, Inc.Analyte testing method and device for calculating basal insulin therapy
US869079629 sept. 20068 avr. 2014Sanofi-Aventis Deutschland GmbhMethod and apparatus for penetrating tissue
US870262429 janv. 201022 avr. 2014Sanofi-Aventis Deutschland GmbhAnalyte measurement device with a single shot actuator
US87216716 juil. 200513 mai 2014Sanofi-Aventis Deutschland GmbhElectric lancet actuator
US87447766 juin 20113 juin 2014Bayer Healthcare LlcMethod for determining analyte concentration based on complex index functions
US878433525 juil. 200822 juil. 2014Sanofi-Aventis Deutschland GmbhBody fluid sampling device with a capacitive sensor
US880820115 janv. 200819 août 2014Sanofi-Aventis Deutschland GmbhMethods and apparatus for penetrating tissue
US882820320 mai 20059 sept. 2014Sanofi-Aventis Deutschland GmbhPrintable hydrogels for biosensors
US88455492 déc. 200830 sept. 2014Sanofi-Aventis Deutschland GmbhMethod for penetrating tissue
US88455503 déc. 201230 sept. 2014Sanofi-Aventis Deutschland GmbhTissue penetration device
US887703528 mars 20134 nov. 2014Bayer Healthcare LlcGated amperometry methods
US890594529 mars 20129 déc. 2014Dominique M. FreemanMethod and apparatus for penetrating tissue
US891718420 mars 200923 déc. 2014Lifescan Scotland LimitedAnalyte testing method and system
US894591019 juin 20123 févr. 2015Sanofi-Aventis Deutschland GmbhMethod and apparatus for an improved sample capture device
US896547618 avr. 201124 févr. 2015Sanofi-Aventis Deutschland GmbhTissue penetration device
US897438730 juin 201010 mars 2015Lifescan Scotland LimitedAnalyte testing method and device for diabetes management
US900552729 mai 201314 avr. 2015Bayer Healthcare LlcTransient decay amperometry biosensors
US90175434 avr. 201328 avr. 2015Roche Diagnostics Operations, Inc.Method for determining the concentration of an analyte in a liquid sample using small volume samples and fast test times
US901754427 juin 201328 avr. 2015Roche Diagnostics Operations, Inc.Determining blood glucose in a small volume sample receiving cavity and in a short time period
US903416021 févr. 201219 mai 2015Bayer Healthcare LlcRapid-read gated amperometry devices
US903463926 juin 201219 mai 2015Sanofi-Aventis Deutschland GmbhMethod and apparatus using optical techniques to measure analyte levels
US907284231 juil. 20137 juil. 2015Sanofi-Aventis Deutschland GmbhMethod and apparatus for penetrating tissue
US908929416 janv. 201428 juil. 2015Sanofi-Aventis Deutschland GmbhAnalyte measurement device with a single shot actuator
US908967821 mai 201228 juil. 2015Sanofi-Aventis Deutschland GmbhMethod and apparatus for penetrating tissue
US911001320 déc. 201318 août 2015Bayer Healthcare LlcGated voltammetry methods
US914440112 déc. 200529 sept. 2015Sanofi-Aventis Deutschland GmbhLow pain penetrating member
US916407627 mai 201120 oct. 2015Bayer Healthcare LlcSlope-based compensation including secondary output signals
US918646814 janv. 201417 nov. 2015Sanofi-Aventis Deutschland GmbhMethod and apparatus for penetrating tissue
US92266999 nov. 20105 janv. 2016Sanofi-Aventis Deutschland GmbhBody fluid sampling module with a continuous compression tissue interface surface
US924826718 juil. 20132 févr. 2016Sanofi-Aventis Deustchland GmbhTissue penetration device
US92614761 avr. 201416 févr. 2016Sanofi SaPrintable hydrogel for biosensors
US931419411 janv. 200719 avr. 2016Sanofi-Aventis Deutschland GmbhTissue penetration device
US933961216 déc. 200817 mai 2016Sanofi-Aventis Deutschland GmbhTissue penetration device
US935168014 oct. 200431 mai 2016Sanofi-Aventis Deutschland GmbhMethod and apparatus for a variable user interface
US937516929 janv. 201028 juin 2016Sanofi-Aventis Deutschland GmbhCam drive for managing disposable penetrating member actions with a single motor and motor and control system
US938694410 avr. 200912 juil. 2016Sanofi-Aventis Deutschland GmbhMethod and apparatus for analyte detecting device
US941091728 févr. 20149 août 2016Ascensia Diabetes Care Holdings AgMethod of using a biosensor
US942753229 sept. 201430 août 2016Sanofi-Aventis Deutschland GmbhTissue penetration device
US949816029 sept. 201422 nov. 2016Sanofi-Aventis Deutschland GmbhMethod for penetrating tissue
US956099320 déc. 20137 févr. 2017Sanofi-Aventis Deutschland GmbhBlood testing apparatus having a rotatable cartridge with multiple lancing elements and testing means
US956100010 déc. 20137 févr. 2017Sanofi-Aventis Deutschland GmbhMethod and apparatus for improving fluidic flow and sample capture
US956374329 juin 20107 févr. 2017Lifescan Scotland LimitedAnalyte testing method and system with high and low blood glucose trends notification
US962648021 nov. 201418 avr. 2017Lifescan Scotland LimitedAnalyte testing method and system
US963865824 avr. 20152 mai 2017Roche Diabetes Care, Inc.Determining blood glucose in a small volume sample receiving cavity and in a short time period
US965818324 avr. 201523 mai 2017Roche Diabetes Care, Inc.Method for determining the concentration of an analyte in a liquid sample using small volume samples and fast test times
US96941443 déc. 20134 juil. 2017Sanofi-Aventis Deutschland GmbhSampling module device and method
US97240218 déc. 20148 août 2017Sanofi-Aventis Deutschland GmbhMethod and apparatus for penetrating tissue
US97755531 oct. 20083 oct. 2017Sanofi-Aventis Deutschland GmbhMethod and apparatus for a fluid sampling device
US977580620 sept. 20123 oct. 2017Ascensia Diabetes Care Holdings AgAnalysis compensation including segmented signals
US97953349 juil. 200724 oct. 2017Sanofi-Aventis Deutschland GmbhMethod and apparatus for penetrating tissue
US97957472 juin 201124 oct. 2017Sanofi-Aventis Deutschland GmbhMethods and apparatus for lancet actuation
US980200718 nov. 201331 oct. 2017Sanofi-Aventis Deutschland GmbhMethods and apparatus for lancet actuation
US20030116447 *4 oct. 200226 juin 2003Surridge Nigel A.Electrodes, methods, apparatuses comprising micro-electrode arrays
US20030155237 *4 oct. 200221 août 2003Surridge Nigel A.Electrodes, methods, apparatuses comprising micro-electrode arrays
US20040031682 *5 mars 200319 févr. 2004Wilsey Christopher D.Method for determining the concentration of an analyte in a liquid sample using small volume samples and fast test times
US20070074977 *30 sept. 20055 avr. 2007Lifescan, Inc.Method and apparatus for rapid electrochemical analysis
US20070161070 *22 févr. 200712 juil. 2007Wilsey Christopher DMethod for determining the concentration of an analyte in a liquid sample using small volume samples and fast test times
US20070170054 *5 mars 200326 juil. 2007Roche Diagnostics Operations, Inc.Method for determining the concentration of an analyte in a liquid sample using small volume samples and fast test times
US20070170055 *4 oct. 200226 juil. 2007Roche Diagnostics Operations, Inc.Electrodes, methods, apparatuses comprising micro-electrode arrays
US20070231914 *13 mai 20054 oct. 2007Yingping DengMethods for Performing Hematocrit Adjustment in Glucose Assays and Devices for Same
US20090026094 *6 mai 200829 janv. 2009Home Diagnostics, Inc.Two-pulse systems and methods for determining analyte concentration
US20090145779 *14 nov. 200811 juin 2009Bayer Healthcare LlcRapid-Read Gated Amperometry
US20090177406 *8 déc. 20089 juil. 2009Bayer Healthcare LlcSlope-Based Compensation
US20090242428 *3 juin 20091 oct. 2009Wilsey Christopher DMethod for determining the concentration of an analyte in a liquid sample using small volume samples and fast test times
US20100270178 *2 juil. 201028 oct. 2010Lifescan, Inc.Method And Apparatus For Rapid Electrochemical Analysis
US20100331654 *30 juin 201030 déc. 2010Lifescan Scotland Ltd.Systems for diabetes management and methods
US20100332142 *30 juin 201030 déc. 2010Lifescan,Inc.Analyte testing method and device for calculating basal insulin therapy
US20110073494 *3 sept. 201031 mars 2011Lifescan Scotland, Ltd.Analyte measurment method and system
US20110205064 *29 juin 201025 août 2011Lifescan Scotland Ltd.Analyte testing method and system with high and low blood glucose trends notification
US20110231105 *22 mars 201122 sept. 2011Bayer Healthcare LlcResidual Compensation Including Underfill Error
USD61115110 juin 20082 mars 2010Lifescan Scotland, Ltd.Test meter
USD61137219 sept. 20089 mars 2010Lifescan Scotland LimitedAnalyte test meter
USD61148925 juil. 20089 mars 2010Lifescan, Inc.User interface display for a glucose meter
USD61185321 mars 200816 mars 2010Lifescan Scotland LimitedAnalyte test meter
USD6122749 sept. 200823 mars 2010Lifescan Scotland, Ltd.User interface in an analyte meter
USD61227521 mars 200823 mars 2010Lifescan Scotland, Ltd.Analyte test meter
USD61227918 janv. 200823 mars 2010Lifescan Scotland LimitedUser interface in an analyte meter
USD61543121 mars 200811 mai 2010Lifescan Scotland LimitedAnalyte test meter
CN102625913A *6 sept. 20101 août 2012生命扫描苏格兰有限公司Glucose measurement method and system
EP1770396A2 *29 sept. 20064 avr. 2007Lifescan, Inc.Method and apparatus for rapid electrochemical analysis
EP1770396A3 *29 sept. 20069 avr. 2008Lifescan, Inc.Method and apparatus for rapid electrochemical analysis
EP1839571A1 *30 mars 20073 oct. 2007LifeScan, Inc.Methods for analyzing a sample in the presence of interferents
EP2263521A1 *30 mars 200722 déc. 2010LifeScan, Inc.Methods for analyzing a sample in the presence of interferents
EP2263522A1 *30 mars 200722 déc. 2010LifeScan, Inc.Methods for analyzing a sample in the presence of interferents
EP2266455A1 *30 mars 200729 déc. 2010LifeScan, Inc.Methods for analyzing a sample in the presence of interferents
EP2634572A3 *6 sept. 201025 mai 2016Lifescan Scotland LimitedGlucose measurement method and system
WO2008141076A1 *8 mai 200820 nov. 2008Home Diagnostics, Inc.Two-pulse systems and methods for determining analyte concentration
WO2011030093A1 *6 sept. 201017 mars 2011Lifescan Scotland LimitedGlucose measurement method and system
Classifications
Classification aux États-Unis436/70, 204/450
Classification internationaleG01N27/327, G01N33/483, A61B5/145, G01N33/66, G01N27/26, G01N33/96, G01N27/416, G01N33/487
Classification coopérativeG01N27/3274
Classification européenneG01N27/327B
Événements juridiques
DateCodeÉvénementDescription
1 nov. 2004ASAssignment
Owner name: LIFESCAN, INC., CALIFORNIA
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:OHARA, TIMOTHY;KERMANI, MAHYAR Z.;REEL/FRAME:015955/0261;SIGNING DATES FROM 20000131 TO 20000201